Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsChildren and adolescents with venous thromboembolism, particularly children aged 4 years or younger, face a higher risk for mortality and economic burden.
Block reversal using sugammadex is associated with better respiratory outcomes than that using neostigmine in adults undergoing upper gastrointestinal endoscopic procedures, a study finds.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.
3.
A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.
4.
Scientists call into question safety of potential new anticancer treatment
5.
Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy
1.
Prognostic Role of PLAU in Pan-Cancer and Neutrophil Infiltration in Bladder Cancer
2.
The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies
3.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
4.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
3.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
4.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
5.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge